NETkids: Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix

Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other)
Overall Status
Recruiting
CT.gov ID
NCT05919758
Collaborator
(none)
1,000
1
25
39.9

Study Details

Study Description

Brief Summary

The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children.

.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Aim Current guidelines recommend complementary right-sided hemicolectomy for high-risk (pT2(with risk factors)/pT3) neuro-endocrine tumors (NET) of the appendix (based on adult studies). In contrast to adults, high-risk NET of the appendix in children seems to be a relatively benign disease with high disease-free survival (100% versus 70-80% in adults), but high quality data are lacking. Therefore these recommendations are now being questioned. We aim to investigate the value of complementary right-sided hemicolectomy for children with high-risk NET of the appendix. Ultimately leading to the development of a consensus guideline and solid information for patients/parents.

    Plan of investigation In order to generate big data, an international historical cohort study is planned to compare complementary right-sided hemicolectomy with appendectomy alone for children with high-risk NET of the appendix. Results will be CONFIDENTIAL used by an international expert group to formulate treatment recommendations. Subsequently, these recommendations will be tested in an international Delphi study in order to develop a consensus guideline on the treatment of pediatric high-risk NET of the appendix.

    Expected results The cohort study will generate high quality information on overall/disease-free survival, recurrence, complications, costs, and hr-QoL. Recommendations made will be tested in a Delphi study; not only on the beneficial value of complementary right-sided hemicolectomy, but also on follow-up protocols and preoperative work-up. Ultimately, an international consensus guideline that redefines low-risk and high-risk NET of the appendix will be developed, leading to global de-escalation and uniformity of treatment.

    Relevance for childhood cancer Results are relevant for pediatric oncologists/surgeons/gastro-enterologists across the world, as redefining low-risk and high-risk patient groups, will lead to de-escalation of treatment. Furthermore, QoL of child and parents can be improved by reducing exposure to complications after complementary right-sided hemicolectomy, and by reducing the fear of recurrence by obtaining high-quality data to accurately inform patients and parents.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Value of Complementary Right-sided Hemicolectomy for Pediatric Patients With High-risk Neuroendocrine Tumors (NETs) of the Appendix; Towards the Development of an (Inter-) National Consensus Guideline for the Pediatric Population.
    Actual Study Start Date :
    May 1, 2023
    Anticipated Primary Completion Date :
    Jun 1, 2024
    Anticipated Study Completion Date :
    Jun 1, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Disease free survival rate [cross-sectional design. follow-up will be done in 2023/2024]

      defined as alive and free of recurrence of NET at telephone follow-up performed for this study purpose

    2. Recurrence rate [cross-sectional design. follow-up will be done in 2023/2024]

      defined as histopathologically proven metastasis/residual tumor at appendiceal stump of NET after a disease free period

    Secondary Outcome Measures

    1. Overall survival rate [cross-sectional design. follow-up will be done in 2023/2024]

      defined as alive at telephone follow-up performed for this study purpose

    2. Complications directly related to primary and secondary treatment divided into major and minor complications according to Clavien-dindo. [cross-sectional design. follow-up will be done in 2023/2024]

      Complications include, but are not limited to: Intra-abdominal abscess, defined as a radiologically confirmed accumulation of purulent fluid in a walled-off space within the abdominal cavity. (Adhesive) bowel obstruction requiring readmission (diagnosis based on clinical signs and symptoms such as a history of constipation, nausea, vomiting and distended abdomen) Superficial Surgical Site Infection, as defined by the CDC criteria. (see table 1.) Deep Surgical Site Infection, as defined by the CDC criteria.

    3. Number of hospital readmission for complications related to treatment of NET [cross-sectional design. follow-up will be done in 2023/2024]

      see title

    4. Length of hospital stay [cross-sectional design. follow-up will be done in 2023/2024]

      initial and total length of stay

    5. number of imaging studies performed for follow-up of NET [cross-sectional design. follow-up will be done in 2023/2024]

      ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), octreotide scintigraphy, PET-CT

    6. Number of outpatient check-ups(regular visits / telephone call) for follow-up of NET [cross-sectional design. follow-up will be done in 2023/2024]

      see title

    7. Health related Quality of Life at follow-up moment for this study [cross-sectional design. follow-up will be done in 2023/2024]

      measured by the PedsQL(generic)

    8. Health related Quality of Life at follow-up moment for this study [cross-sectional design. follow-up will be done in 2023/2024]

      measured by the QLQ-C30(generic)

    9. Health related Quality of Life at follow-up moment for this study [cross-sectional design. follow-up will be done in 2023/2024]

      measured by the QLQ-GINET-21 questionnaire(disease specific)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 17 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • All patients that were treated for an appendiceal NET before the age of 18 years old

    • Time period: 1990-2020

    Exclusion Criteria:
    • Other appendiceal malignancies/tumours, for example:

    • goblet cell carcinoma

    • adenocarcinoma

    • neuroendocrine carcinoma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Amsterdam UMC Amsterdam-Zuidoost Netherlands

    Sponsors and Collaborators

    • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    Investigators

    • Study Chair: Ramon R Gorter, MD PhD, Amsterdam UMC, department of pediatric surgery

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ramon Gorter, Principal investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    ClinicalTrials.gov Identifier:
    NCT05919758
    Other Study ID Numbers:
    • W21_169#21.184
    First Posted:
    Jun 26, 2023
    Last Update Posted:
    Jun 26, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 26, 2023